American pharmaceutical company Moderna (MRNA) is reportedly under scrutiny by U.S. President Donald Trump’s team, which is ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake challenges.

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Moderna’s Q4 2024 earnings call highlighted its ongoing challenges in the respiratory vaccine market and its ... while cost reductions and a cash cost target of $5.5 billion in 2025 demonstrate ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

Along with the downgrade, the firm lowered its price target to $45 following ... One notable issue is Moderna's Phase 3 norovirus vaccine trial (mRNA-1403), which was placed on clinical hold ...

The FDA has canceled an advisory committee's meeting on flu shot recommendations, raising concerns amid shifts in leadership ...